Download PDF
Thromb Haemost
DOI: 10.1055/a-2632-3001
Coagulation and Fibrinolysis

Implementing an Assay Detecting Anti-drug Antibody against Emicizumab: Experience from One Center in France

Claire Auditeau 
1   Laboratoire d'Hématologie Biologique, AP-HP, Hôpital Necker Enfants Malades, Paris, France
2   HITh, UMR_S 1176, INSERM, Univ. Paris-Saclay, Le Kremlin-Bicêtre, France
,
Carla Valsecchi 
3   Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy
,
Nûn Kalim Bentounes
1   Laboratoire d'Hématologie Biologique, AP-HP, Hôpital Necker Enfants Malades, Paris, France
,
Amandine Le-Goff
1   Laboratoire d'Hématologie Biologique, AP-HP, Hôpital Necker Enfants Malades, Paris, France
,
Annie Harroche
4   Centre de Traitement de l'Hémophilie, AP-HP, Hôpital Necker Enfants Malades, Paris, France
,
Cécile Bally
4   Centre de Traitement de l'Hémophilie, AP-HP, Hôpital Necker Enfants Malades, Paris, France
,
Peter J. Lenting
2   HITh, UMR_S 1176, INSERM, Univ. Paris-Saclay, Le Kremlin-Bicêtre, France
,
Delphine Borgel
1   Laboratoire d'Hématologie Biologique, AP-HP, Hôpital Necker Enfants Malades, Paris, France
2   HITh, UMR_S 1176, INSERM, Univ. Paris-Saclay, Le Kremlin-Bicêtre, France
,
Flora Peyvandi
3   Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy
5   Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy
,
Dominique Lasne 
1   Laboratoire d'Hématologie Biologique, AP-HP, Hôpital Necker Enfants Malades, Paris, France
2   HITh, UMR_S 1176, INSERM, Univ. Paris-Saclay, Le Kremlin-Bicêtre, France
› Author Affiliations
Funding F.P. was partially supported by the Italian Ministry of Health – Bando Ricerca Corrente. The Hemostasis & Thrombosis Unit of the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico is a member of the European Reference Network on Rare Haematological Diseases EuroBloodNet-Project ID No. 101157011. ERN-EuroBloodNet is partly co-funded by the European Union within the framework of the Fourth EU Health Program.
› Further Information
   Permissions and Reprints


Abstract

Background

Emicizumab is an antibody that mimics the function of factor (F)VIII and has been approved for prophylaxis in hemophilia A patients. However, the development of anti-drug antibodies (ADA) against emicizumab, although rare, can impair its efficacy. In cases with low drug levels or bleeding events, differentiating between ADA- and adherence-related issues can be challenging.

Material and Methods

We aimed at evaluating the effectiveness of a modified bridging ELISA (Valsecchi et al, JTH 2021) in detecting ADA in patients suspected of developing this response. Clinical and laboratory data were retrospectively collected from six patients with suspected ADA and one with a confirmed case. The modified ELISA was performed blindly to identify potential ADA presence. After a new ADA case was confirmed, it was characterized by assessing its expression over time and neutralizing effect.

Results

Five patients had emicizumab levels ≤1 µg/mL, while two had higher levels (13 and 15 µg/mL). Among the patients, two experienced spontaneous bleeding, and four had traumatic bleeding. ADA was detected in two patients, including the one with a known ADA. In ADA-negative patients, emicizumab levels increased following adjustments for compliance or administration issues. The newly identified ADA was neutralizing, blocking emicizumab's binding to factors IX and X. Its pattern of expression was similar to that of the known ADA case, peaking 3 months after the loss of emicizumab efficacy and remaining positive for over a year after emicizumab discontinuation.

Conclusion

In bleeding patients with low emicizumab levels, the modified bridging ELISA may effectively differentiate ADA patients from those with other issues leading to decreased emicizumab concentration.

Keywords

hemophilia therapy - emicizumab - anti-drug antibodies - hemostasis - hemophilia A/B

Authors' Contribution

C.A., C.V., N.K.B., and A.L.G. performed experiments; C.B. and A.H. collected the data; C.A., D.B, C.V., F.P., and D.L. designed the study; C.A. and D.L. supervised the study; C.A., C.V., and P.J.L. analyzed and interpreted the data; C.A. wrote the manuscript. All authors revised the manuscript critically and approved the version to be submitted.


Supplementary Material



Publication History

Received: 05 November 2024

Accepted: 10 June 2025

Accepted Manuscript online:
11 June 2025

Article published online:
27 June 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • References

  • 1 Oldenburg J, Mahlangu JN, Kim B. et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377 (09) 809-818
    CrossrefPubMedSearch in Google Scholar
  • 2 Mahlangu J, Oldenburg J, Paz-Priel I. et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med 2018; 379 (09) 811-822
    CrossrefPubMedSearch in Google Scholar
  • 3 Pipe SW, Shima M, Lehle M. et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol 2019; 6 (06) e295-e305
    CrossrefPubMedSearch in Google Scholar
  • 4 Young G, Liesner R, Chang T. et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood 2019; 134 (24) 2127-2138
    CrossrefPubMedSearch in Google Scholar
  • 5 Hassan E, Jonathan L, Jayashree M. Real-world experience on the tolerability and safety of emicizumab prophylaxis in paediatric patients with severe haemophilia A with and without FVIII inhibitors. Haemophilia 2021; 27 (06) e698-e703
    CrossrefPubMedSearch in Google Scholar
  • 6 Bush KA, Ding H, O'Flaherty-Keese K. et al. Real-world clinical outcomes in previously untreated and minimally treated patients with congenital factor VIII deficiency: the San Diego experience. Blood 2020; 136(Suppl 1): 31-32
    CrossrefPubMedSearch in Google Scholar
  • 7 Misgav M, Brutman-Barazani T, Budnik I. et al. Emicizumab prophylaxis in haemophilia patients older than 50 years with cardiovascular risk factors: real-world data. Haemophilia 2021; 27 (02) 253-260
    PubMedSearch in Google Scholar
  • 8 Young G, Pipe SW, Kenet G. et al. Emicizumab is well tolerated and effective in people with congenital hemophilia A regardless of age, severity of disease, or inhibitor status: a scoping review. Res Pract Thromb Haemost 2024; 8 (04) 102415
    CrossrefPubMedSearch in Google Scholar
  • 9 Schmitt C, Emrich T, Chebon S. et al. Low immunogenicity of emicizumab in persons with haemophilia A. Haemophilia 2021; 27 (06) 984-992
    CrossrefPubMedSearch in Google Scholar
  • 10 Harkins Druzgal C, Kizilocak H, Brown J, Sennett M, Young G. Neutralizing antidrug antibody to emicizumab in a patient with severe hemophilia A with inhibitors: new case with detailed laboratory evaluation. J Thromb Haemost 2020; 18 (09) 2205-2208
    CrossrefPubMedSearch in Google Scholar
  • 11 Valsecchi C, Gobbi M, Beeg M. et al. Characterization of the neutralizing anti-emicizumab antibody in a patient with hemophilia A and inhibitor. J Thromb Haemost 2021; 19 (03) 711-718
    CrossrefPubMedSearch in Google Scholar
  • 12 Harroche A, Sefiane T, Desvages M. et al. Non-inhibitory antibodies inducing increased emicizumab clearance in a severe haemophilia A inhibitor patient. Haematologica 2021; 106 (08) 2287-2290
    CrossrefPubMedSearch in Google Scholar
  • 13 Kaneda M, Kawasaki R, Matsumoto N. et al. Detailed analysis of anti-emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A. J Thromb Haemost 2021; 19 (12) 2938-2946
    CrossrefPubMedSearch in Google Scholar
  • 14 Kizilocak H, Guerrera MF, Young G. Neutralizing antidrug antibody to emicizumab in patients with severe hemophilia A: case report of a first noninhibitor patient and review of the literature. Res Pract Thromb Haemost 2023; 7 (06) 102194
    PubMedSearch in Google Scholar
  • 15 Valsecchi C, Schiavone L, Arcudi S. et al. Development and clinical utility of anti-emicizumab antibody detection assays. (abstract) Res Pract Thromb Haemost 2023; 7 (Suppl 2): 101164
    PubMedSearch in Google Scholar
  • 16 Pezeshkpoor B, Sereda N, Becker-Gotot J. et al. Comprehensive evaluation of anti-emicizumab antibodies in acquired hemophilia A: a detailed case study and methodological evaluation. J Thromb Haemost 2025; 23 (01) 85-96
    PubMedSearch in Google Scholar
  • 17 Nogami K, Soeda T, Matsumoto T, Kawabe Y, Kitazawa T, Shima M. Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies. J Thromb Haemost 2018; 16 (07) 1383-1390
    PubMedSearch in Google Scholar
  • 18 Partridge MA, Purushothama S, Elango C, Lu Y. Emerging technologies and generic assays for the detection of anti-drug antibodies. J Immunol Res 2016; 2016: 6262383
    PubMedSearch in Google Scholar
  • 19 Patton A, Mullenix MC, Swanson SJ, Koren E. An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen. J Immunol Methods 2005; 304 (1-2): 189-195
    CrossrefPubMedSearch in Google Scholar
  • 20 Kavita U, Duo J, Crawford SM. et al. A systematic study of the effect of low pH acid treatment on anti-drug antibodies specific for a domain antibody therapeutic: impact on drug tolerance, assay sensitivity and post-validation method assessment of ADA in clinical serum samples. J Immunol Methods 2017; 448: 91-104
    PubMedSearch in Google Scholar
  • 21 Zoghbi J, Xu Y, Grabert R, Theobald V, Richards S. A breakthrough novel method to resolve the drug and target interference problem in immunogenicity assays. J Immunol Methods 2015; 426: 62-69
    PubMedSearch in Google Scholar
  • 22 Smith HW, Butterfield A, Sun D. Detection of antibodies against therapeutic proteins in the presence of residual therapeutic protein using a solid-phase extraction with acid dissociation (SPEAD) sample treatment prior to ELISA. Regul Toxicol Pharmacol 2007; 49 (03) 230-237
    PubMedSearch in Google Scholar
  • 23 Du J, Yang Y, Zhu L. et al. Method validation of a bridging immunoassay in combination with acid-dissociation and bead treatment for detection of anti-drug antibody. Heliyon 2023; 9 (03) e13999
    PubMedSearch in Google Scholar
  • 24 Emicizumab US Medical Information Site. Accessed August 16, 2024 at: https://www.emicizumabinfo.global/us/en/homepage/faq.html
    PubMed
  • 25 Nieuwlaat R, Wilczynski N, Navarro T. et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2014; 2014 (11) CD000011
    PubMedSearch in Google Scholar
  • 26 Okolo A, Shapiro A, Janson I. et al. Psychometrics and applications of a novel self-report measure of emicizumab adherence: VERITASNexGen. Haemophilia 2023; 29 (05) 1299-1305
    PubMedSearch in Google Scholar
  • 27 Uchida N, Sambe T, Yoneyama K. et al. A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. Blood 2016; 127 (13) 1633-1641
    CrossrefPubMedSearch in Google Scholar
  • 28 Colman RJ, Portocarrero-Castillo A, Chona D, Hellmann J, Minar P, Rosen MJ. Favorable outcomes and anti-TNF durability after addition of an immunomodulator for anti-drug antibodies in pediatric IBD patients. Inflamm Bowel Dis 2021; 27 (04) 507-515
    PubMedSearch in Google Scholar
  • 29 Falsey A, Jo D, Sirak H. et al. Corticosteroids can be used to decrease antidrug antibodies in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2021; 27 (12) e159-e160
    PubMedSearch in Google Scholar